These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37728975)

  • 21. Perceptions of network based recruitment for hepatitis C testing and treatment among persons who inject drugs: a qualitative exploration.
    Ward KM; McCormick SD; Sulkowski M; Latkin C; Chander G; Falade-Nwulia O
    Int J Drug Policy; 2021 Feb; 88():103019. PubMed ID: 33160152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Engaging people who use drugs in clinical research: integrating facilitated telemedicine for HCV into substance use treatment.
    Talal AH; George SJ; Talal LA; Dharia A; Ventuneac A; Baciewicz G; Perumalswami PV; Dickerson SS
    Res Involv Engagem; 2023 Aug; 9(1):63. PubMed ID: 37533127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment for hepatitis C virus with direct acting antiviral agents: Perspectives and treatment experiences of people who inject drugs.
    Karasz A; Singh R; McKee MD; Merchant K; Kim AY; Page K; Pericot-Valverde I; Stein ES; Taylor LE; Wagner K; Litwin AH
    J Subst Abuse Treat; 2022 Sep; 140():108768. PubMed ID: 35729038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus risk among young people who inject drugs.
    Mateu-Gelabert P; Sabounchi NS; Guarino H; Ciervo C; Joseph K; Eckhardt BJ; Fong C; Kapadia SN; Huang TTK
    Front Public Health; 2022; 10():835836. PubMed ID: 35968435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Barriers to hepatitis C treatment among secondary needle and syringe program clients and opportunities to intervene.
    Gunn J; McNally S; Ryan J; Layton C; Bryant M; Walker S; O'Mahony C; Pedrana A
    Int J Drug Policy; 2021 Oct; 96():103387. PubMed ID: 34330571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study.
    Zelenev A; Li J; Mazhnaya A; Basu S; Altice FL
    Lancet Infect Dis; 2018 Feb; 18(2):215-224. PubMed ID: 29153265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of and risk factors for hepatitis C virus antibody among people who inject drugs in Cambodia: a national biological and behavioral survey.
    Yi S; Mun P; Chhoun P; Chann N; Tuot S; Mburu G
    Harm Reduct J; 2019 Apr; 16(1):29. PubMed ID: 31036011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV and hepatitis B and C co-infection among people who inject drugs in Zanzibar.
    Khatib A; Matiko E; Khalid F; Welty S; Ali A; Othman A; Haji S; Dahoma M; Rutherford G
    BMC Public Health; 2017 Nov; 17(1):917. PubMed ID: 29183287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis.
    Cunningham EB; Wheeler A; Hajarizadeh B; French CE; Roche R; Marshall AD; Fontaine G; Conway A; Bajis S; Valencia BM; Presseau J; Ward JW; Degenhardt L; Dore GJ; Hickman M; Vickerman P; Grebely J
    Int J Drug Policy; 2023 Jan; 111():103917. PubMed ID: 36542883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C Virus-HIV Coinfection in the United States Among People Who Inject Drugs: Data Needed for Ending Dual Epidemics.
    Moorman AC; Bixler D; Teshale EH; Hofmeister M; Roberts H; Chapin-Bardales J; Gupta N
    Public Health Rep; 2023 Jul; ():333549231181348. PubMed ID: 37480274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.
    Akiyama MJ; Cleland CM; Lizcano JA; Cherutich P; Kurth AE
    Lancet Infect Dis; 2019 Nov; 19(11):1255-1263. PubMed ID: 31540840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C antibody prevalence, correlates and barriers to care among people who inject drugs in Central California.
    Ozga JE; Syvertsen JL; Pollini RA
    J Viral Hepat; 2022 Jul; 29(7):518-528. PubMed ID: 35357738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. "Stigma is where the harm comes from": Exploring expectations and lived experiences of hepatitis C virus post-treatment trajectories among people who inject drugs.
    Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
    Int J Drug Policy; 2021 Oct; 96():103238. PubMed ID: 33902968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India.
    Patel EU; Solomon SS; Mcfall AM; Srikrishnan AK; Pradeep A; Nandagopal P; Laeyendecker O; Tobian AAR; Thomas DL; Sulkowski MS; Kumar MS; Mehta SH
    Int J Drug Policy; 2018 Jul; 57():51-60. PubMed ID: 29679811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Motivations, facilitators and barriers to accessing hepatitis C treatment among people who inject drugs in two South African cities.
    Versfeld A; McBride A; Scheibe A; Spearman CW
    Harm Reduct J; 2020 Jun; 17(1):39. PubMed ID: 32522210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review.
    Degenhardt L; Webb P; Colledge-Frisby S; Ireland J; Wheeler A; Ottaviano S; Willing A; Kairouz A; Cunningham EB; Hajarizadeh B; Leung J; Tran LT; Price O; Peacock A; Vickerman P; Farrell M; Dore GJ; Hickman M; Grebely J
    Lancet Glob Health; 2023 May; 11(5):e659-e672. PubMed ID: 36996857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring and understanding HCV patient journeys- HEPCARE Europe project.
    Glaspy S; Avramovic G; McHugh T; Oprea C; Surey J; Ianache I; Macías J; Story A; Cullen W; Lambert JS
    BMC Infect Dis; 2021 Mar; 21(1):239. PubMed ID: 33673828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Barriers to accessing sterile injecting equipment for people who inject drugs: An integrative review.
    Lawson E; Walthall H
    J Clin Nurs; 2023 Aug; 32(15-16):4502-4514. PubMed ID: 36068712
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.